New Hope is part of the Global Exhibitions Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

NBJ
opioids

FDA targets supplements making opioid withdrawal claims

The opioid crisis has spurred several supplement brands to make claims about easing withdrawal symptoms and making quitting easier, but such brands are currently facing legal action.

A “health crisis” would suggest an all-hands-on-deck response, but does the most-talked-about​ ​​​​​​crisis of the moment require a different approach? Regulators would say yes.

And the supplements industry is listening.

A number of “dietary supplement” marketers in the United States have targeted opioid addicts, drawing the unwelcome attention of federal regulators who oversee the labeling and marketing of such products. Actions taken earlier this year by the FDA and Federal Trade Commission highlight those regulators’ long-held concern over the nation’s opioid epidemic and risks associated with claims that a supplement can treat a disease. In January, the two federal agencies jointly issued 11 warning letters to companies for making unproven claims that their products can aid in the treatment of opioid addiction and withdrawal.

The FTC sent four additional letters to marketers of opioid-cessation products. “The FDA is increasingly concerned with the proliferation of products claiming to treat or cure serious diseases like opioid addiction and withdrawal,” FDA Commissioner Scott Gottlieb said in a statement, announcing the federal agencies’ warning letters.

Several companies targeted had been investigated previously by the Center for Science in the Public Interest (CSPI), a consumer watchdog group in Washington.“The FDA and FTC’s decision to warn these exploitative companies could save consumers’ lives and is a very welcome step,” CSPI President Peter Lurie said in a statement. “These ineffective withdrawal aids pose an imminent danger to very vulnerable consumers who are desperate to treat their opioid addiction.”

Among the claims that captured regulators’ attention:

• “#1 Selling Opiate Withdrawal Brand”

• “Imagine a life without the irritability, cravings, restlessness, excitability, exhaustion and discomfort associated with the

nightmare of addiction and withdrawal symptoms”

• “Safe and effective natural supplements that work to ease many physical symptoms of opiate withdrawal”

• “Break the pain killer habit”

• “Relieve Your Symptoms… addiction, withdrawal, cravings.”

The warning letters reflect efforts by the federal government to protect a vulnerable population in a national crisis. “People who are addicted to opioids should have access to safe and effective treatments and not be victimized by unscrupulous vendors who are trying to capitalize on the opioid epidemic by taking advantage of consumers and selling products with baseless claims,” Gottlieb said.

In 2016 alone, opioids were involved in more than 42,000 deaths, according to the Centers for Disease Control and Prevention. The warning letters raised separate but related concerns within the respective wheelhouses of FDA and FTC: whether the companies were making so-called disease claims that rendered their products unapproved new drugs and whether the marketing claims were adequately substantiated with scientific evidence.

“If you look at the types of claims made, effectively you have products that are holding themselves out as appropriate for treatment of opioid addiction,” says Donnelly McDowell, an associate with Kelley Drye & Warren LLP.

Under the circumstances, FDA considers such products to be unapproved new drugs.

 

NBJ End-of-the-Year Sale: This content is republished from the Nutrition Business Journal’s Condition Specific Report, an exploration of insight, trends and sales data for executives, investors, product developers and marketing teams on sale now at the deepest discounts of the years. Contact NBJ Business Development Manager Cindy Van Schouwen at cvanschouwen@newhope.com, (303) 998-9305.

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish